CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
CytomX Therapeutics (Nasdaq: CTMX), a company specializing in masked, conditionally activated biologic therapeutics, has scheduled the release of its fourth quarter and full year 2024 financial results for March 6, 2025, after U.S. markets close.
The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT on the same day. Interested participants can access the webcast through CytomX's investor relations website and are advised to register at least 10 minutes before the call begins.
CytomX Therapeutics (Nasdaq: CTMX), un'azienda specializzata in terapie biologiche mascherate e attivate condizionalmente, ha programmato la pubblicazione dei suoi risultati finanziari del quarto trimestre e dell'anno intero 2024 per il 6 marzo 2025, dopo la chiusura dei mercati statunitensi.
L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 17:00 ET / 14:00 PT lo stesso giorno. I partecipanti interessati possono accedere alla trasmissione attraverso il sito web delle relazioni con gli investitori di CytomX e si consiglia di registrarsi almeno 10 minuti prima dell'inizio della chiamata.
CytomX Therapeutics (Nasdaq: CTMX), una empresa especializada en terapias biológicas enmascaradas y activadas condicionalmente, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 6 de marzo de 2025, después del cierre de los mercados de EE. UU.
La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo a las 5:00 p.m. ET / 2:00 p.m. PT el mismo día. Los participantes interesados pueden acceder a la transmisión a través del sitio web de relaciones con inversores de CytomX y se les aconseja registrarse al menos 10 minutos antes de que comience la llamada.
사이톰엑스 테라퓨틱스 (Nasdaq: CTMX), 조건부로 활성화된 생물학적 치료제에 특화된 회사는 2024년 4분기 및 전체 연도 재무 결과를 2025년 3월 6일 미국 시장 종료 후 발표할 예정입니다.
회사는 같은 날 오후 5시(ET) / 오후 2시(PT)에 전화 회의 및 웹캐스트를 개최합니다. 관심 있는 참가자는 CytomX의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 통화 시작 10분 전까지 등록할 것을 권장합니다.
CytomX Therapeutics (Nasdaq: CTMX), une entreprise spécialisée dans les thérapies biologiques masquées et activées conditionnellement, a programmé la publication de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 6 mars 2025, après la fermeture des marchés américains.
La société organisera une conférence téléphonique et un webinaire à 17h00 ET / 14h00 PT le même jour. Les participants intéressés peuvent accéder au webinaire via le site Web des relations avec les investisseurs de CytomX et sont invités à s'inscrire au moins 10 minutes avant le début de l'appel.
CytomX Therapeutics (Nasdaq: CTMX), ein Unternehmen, das sich auf maskierte, bedingt aktivierte biopharmazeutische Therapien spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 6. März 2025 nach Börsenschluss in den USA geplant.
Das Unternehmen wird am selben Tag um 17:00 Uhr ET / 14:00 Uhr PT eine Telefonkonferenz und ein Webcast veranstalten. Interessierte Teilnehmer können über die Investor-Relations-Website von CytomX auf den Webcast zugreifen und werden gebeten, sich mindestens 10 Minuten vor Beginn des Anrufs anzumelden.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
When will CytomX Therapeutics (CTMX) release its Q4 and full year 2024 earnings?
What time is the CTMX Q4 2024 earnings conference call?
How can investors access CTMX's Q4 2024 earnings webcast?
What is the registration requirement for CTMX's Q4 2024 earnings call?
